Cargando...
Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma
Recently, bendamustine has become an important agent in the treatment for patients with lymphoid malignancies. Although the drug has received approval for second-line therapy in indolent lymphoma, a growing body of evidence suggests its efficacy and safety in first-line use. The results of randomise...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer US
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4006123/ https://ncbi.nlm.nih.gov/pubmed/24752517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-014-0944-1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|